Book a meeting

Let's meet. Face-to-face or virtually, the choice is yours.

April Investment Spotlight

 

Property Spotlight: The Strand, Coolangatta QLD


The Strand is a mixed‑use retail and office centre located at 72–80 Marine Parade, Coolangatta, on the southern Gold Coast. It sits on a 2.1‑hectare site with approximately 30,006 sqm of gross lettable area and 664 basement car spaces, directly opposite Coolangatta Beach with over 200 metres of beachfront frontage. m. 

Structure: Unlisted, closed‑end wholesale unit trust.
Purchase Price: $142 million
Forecast Distribution Yield: 9.0% - 10.% p.a paid quartely
Target Returns: 16.0% - 17.0%

The property benefits from proximity to the Gold Coast Airport (around 2.6 km away) and potential future connection to Stage 4 of the Gold Coast Light Rail, which is planned (not committed) to run from Burleigh Heads to Coolangatta via the airport.

The Strand is a 100% freehold interest, originally built in 1988 and substantially refurbished in 2015 (around $60 million) to introduce Woolworths and new waterfront dining. The building is spread across six levels (four levels of retail/office plus two basement carparks) around a central atrium.

Income is diversified: approximately 75% retail and 25% office, with a total Weighted Average Lease Expiry of 5.5 years by income as at 1 August 2025. Retail income includes Woolworths, Cinebar, Timezone, Truckloads, Boardriders/4 Pines, Lincraft and Priceline, plus 63 specialties, 10 kiosks and 2 ATMs. Office income is anchored by health, education and professional tenants such as Feros Care, Attwood Marshall, Mastery Schools Australia, Hillcrest Christian College, NRMA Parks and the Council Library. Asset occupancy is 93.1% by GLA.

The main trade area population is approximately 145,857 (MTA) and 732,509 (TTA), with strong residential price growth: median dwelling values in key suburbs such as Coolangatta and Bilinga have roughly doubled over the past five years. There is a visible pipeline of higher‑end residential projects, growing tourism (around 12.2 million annual visitors to the Gold Coast) and a significant hotel room base in the primary trade area. Worker numbers within 5–10 minutes have also grown at around 5.5% p.a. over the decade to 2021.

Financially, the asset is being acquired at an initial passing yield of 8.0% (9.0% fully leased), equating to $4,732 per sqm of GLA. This represents an estimated ~70% discount to an assessed replacement cost of roughly $480 million, highlighting high barriers to new supply at a similar scale and quality.

Untitled design (24)

Strategy Spotlight: Using Insurance To Equalise An Estate


Many families have most of their wealth tied up in one big asset – a family business, farm, or investment property. That’s great for building wealth, but it can create a real problem when it comes to your estate: how do you treat each child fairly, without forcing the sale of the asset you’ve worked so hard to build?

This is where insurance can be a powerful equalisation tool.

Imagine you have two children. One works in the business and plans to take it over. The other has their own career and no involvement day‑to‑day. If you simply split everything 50/50, your executor may be forced to sell or heavily gear the business to create cash for the non‑business child. That can damage the very asset you’re trying to pass on.

Instead, you can use a life insurance policy to create a pool of cash for the child who won’t receive business equity. Your will might direct that the business shares pass entirely to the child who runs it, while the insurance proceeds (and any other liquid assets) go to the other child or into a testamentary trust for their benefit.

The result is simple:

• The business stays intact and in capable hands
• Each child receives a broadly comparable benefit
• You reduce the risk of disputes, resentment, or rushed decisions at a difficult time.

It’s a practical way to turn a “lumpy” estate into balanced outcomes for the whole family

 

Equity Spotlight: CSL Limited (CSL)

CSL is a global leader in plasma therapies, vaccines and innovative biotech, underpinned by high barriers to entry and robust demand for its treatments. The company continues to invest heavily in research and development, targeting a strong pipeline of new and expanded projects to drive medium‑term growth. Operationally, plasma collection efficiencies, scale advantages and a diversified product base support attractive margins and sustainable free cash flow generation.

While the business is not immune to regulatory, pricing and competitive risks, its scale, intellectual property, and long relationships provide a wide economic moat.

CSL’s share price has declined in value over the last two years, reflecting market sentiment, the risk of tariff’s in the United States and recent weakness in vaccine take-up abroad, however the core business is still functioning productively and the balance sheet remains solid.

For long‑term investors seeking defensive healthcare, CSL remains a high‑quality business.

AdobeStock_46595127
Add title here
Investment Spotlight tsmc
Why-CSL-might-be-undervalued-right-now-0001_tablet
Add title here
Investment Spotlight
Investment Spotlight

Sign up for the latest news and insights

Sign Up